You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The US Department of Health and Human Services (HHS) said that it would use Fluidigm's saliva-based molecular SARS-CoV-2 test as part of a federal surge testing program.
The NGS-based test is intended for use by lab personnel trained to use Illumina's MiSeq and NextSeq systems.
Qiagen has benefited from unexpected tailwinds due to COVID-19 testing and envisions post-pandemic growth with recently acquired NeuMoDx as a key contributor.
Funding for Fluidigm's assay through NIH's RADx program was increased by approximately $22 million for a total contract value of up to about $34 million.
In 2018 Qiagen purchased a 19.9 percent stake in Ann Arbor, Michigan-based NeuMoDx along with the right to acquire the remaining shares.
Reported as "nucleic acid amplification test-detectable" units per milliliter, the limits of detection of more than 50 commercial tests differed by 10,000-fold.
The firm was one of the first to have a COVID-19 test receive EUA from the FDA. It is also developing a COVID-19/flu combo test for which it will seek EUA.
The New York startup is curating available data for all Emergency Use Authorized molecular diagnostic tests for the benefit of the public.
Up to 35 private and public labs in France will be able to use UgenTec's FastFinder analysis software to scale up testing for SARS-CoV-2 and other pathogens.
A letter to users regards inaccurate results due to inadequate sample processing and an issue with interpretive software.